Aztreonam

Chemical formula: C₁₃H₁₇N₅O₈S₂  Molecular mass: 435.433 g/mol  PubChem compound: 5742832

Therapeutic indications

Aztreonam is indicated for:

Chronic pulmonary infections due to Pseudomonas aeruginosa in cystic fibrosis (CF)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Aztreonam is indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Urinary tract infection

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Urinary tract infections: including pyelonephritis and cystitis (initial and recurrent) and asymptomatic bacteriuria, including those due to pathogens resistant to the aminoglycosides, cephalosporins or penicillins.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Gonorrhea

Population group: only adults (18 years old or older)

Acute uncomplicated urogenital or anorectal infections due to beta-lactamase producing or non-producing strains of N. gonorrhoeae.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Lower respiratory tract infections in cystic fibrosis

Population group: only adults (18 years old or older)

Lower respiratory tract infections: including pneumonia, bronchitis and lung infections in patients with cystic fibrosis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Septicaemia

Population group: only adults (18 years old or older)

Bacterial septicemia and additionally at least one of
Gram-negative aerobic rod
Gram-negative aerobic cocci

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial meningitis

Population group: only adults (18 years old or older)

Meningitis caused by Haemophilus influenzae or Neisseria meningitidis. Since aztreonam provides only Gram negative cover, it should not be given alone as initial blind therapy, but may be used with an antibiotic active against Gram positive organisms until the results of sensitivity tests are known.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bone and joint infections, skin and soft tissue infections

Population group: only adults (18 years old or older)

at least one of
Infection of bone
Infectious disorder of joint
Soft tissue infection
and additionally at least one of
Gram-negative aerobic rod
Gram-negative aerobic cocci

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Intra-abdominal infections

Population group: only adults (18 years old or older)

Infectious disease of abdomen and additionally at least one of
Gram-negative aerobic rod
Gram-negative aerobic cocci

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Gynaecological infections

Population group: women, only adults (18 years old or older)

Female genital infection

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Urinary tract infection

Population group: only minors (0 - 18 years old)

Urinary tract infections: including pyelonephritis and cystitis (initial and recurrent) and asymptomatic bacteriuria, including those due to pathogens resistant to the aminoglycosides, cephalosporins or penicillins.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Lower respiratory tract infections in cystic fibrosis

Population group: only minors (0 - 18 years old)

Lower respiratory tract infections: including pneumonia, bronchitis and lung infections in patients with cystic fibrosis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Septicaemia

Population group: only minors (0 - 18 years old)

Bacterial septicemia and additionally at least one of
Gram-negative aerobic rod
Gram-negative aerobic cocci

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial meningitis

Population group: only minors (0 - 18 years old)

Meningitis caused by Haemophilus influenzae or Neisseria meningitidis. Since aztreonam provides only Gram negative cover, it should not be given alone as initial blind therapy, but may be used with an antibiotic active against Gram positive organisms until the results of sensitivity tests are known.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bone and joint infections, skin and soft tissue infections

Population group: only minors (0 - 18 years old)

at least one of
Infection of bone
Infectious disorder of joint
Soft tissue infection
and additionally at least one of
Gram-negative aerobic rod
Gram-negative aerobic cocci

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Intra-abdominal infections

Population group: only minors (0 - 18 years old)

Infectious disease of abdomen and additionally at least one of
Gram-negative aerobic rod
Gram-negative aerobic cocci

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Aztreonam is contraindicated in the following cases:

Hypersensitivity to aztreonam

Aztreonam allergy

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: CAYSTON Powder and solvent for nebuliser solution
Summary of Product Characteristics (SPC) 2019: AZACTAM Powder for solution for injection or infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈